Constipation on Wegovy (semaglutide 2.4 mg): Incidence, Severity, and Realistic Expectations

How common is constipation on Wegovy?

The clearest number comes from the safety database behind the label: three randomized, double-blind, placebo-controlled trials in adults with obesity or overweight, 2,116 people on Wegovy 2.4 mg weekly and 1,261 on placebo, treated for up to 68 weeks [1]. Constipation was reported by 24% on Wegovy and 11% on placebo — roughly 13 extra cases per 100 treated people [1].

The same excess shows up in pooled analyses. A 2024 meta-analysis of nine randomized trials in adults with overweight or obesity but no diabetes (11,641 on semaglutide, 10,479 on placebo) found constipation with an odds ratio of 2.43 (P < 0.0001) versus placebo [2]. A 2025 network meta-analysis of 39 studies covering 33,354 non-diabetic adults with overweight or obesity found semaglutide among the GLP-1 receptor agonists associated with increased constipation risk [3].

Constipation is not the leading gastrointestinal complaint. In the same label table, nausea was reported by 44%, diarrhea by 30% and vomiting by 24% [1]. A 2024 JAMA review of obesity medications put constipation at 11% to 24% for the nutrient-stimulated hormone drugs as a group — liraglutide, semaglutide and tirzepatide [4].

Does a higher dose mean more constipation?

In the label's own comparison, constipation was reported by 20% of 1,311 adults on 7.2 mg, 19% of 304 on 2.4 mg and 8% of 303 on placebo across two 72-week trials [1]. The two active doses landed at nearly the same rate, while nausea (39% vs 35%) and vomiting (22% vs 16%) were somewhat more frequent at 7.2 mg [1].

How severe does it get?

The label does not split constipation into mild, moderate and severe percentages, so any specific breakdown is an estimate rather than a reported finding. What the label does record:

• A warning for severe gastrointestinal adverse reactions, reported in 4.1% of adults on Wegovy injection versus 0.9% on placebo [1]. That figure covers all severe GI reactions, not constipation on its own.
• The Wegovy label lists postmarketing reports of ileus, intestinal obstruction and severe constipation with fecal impaction. Their frequency cannot be estimated from voluntary reports [1].
• A statement in the same warning section that Wegovy is not recommended in patients with severe gastroparesis [1].

Does the tablet form give the same constipation rate?

Wegovy is also sold as 25 mg daily tablets, and the label says the types and frequencies of adverse reactions with the tablet were similar to the injection table [1].

Does it settle down, and what helps?

The label's safety table gives a single rate for the whole treatment period of up to 68 weeks rather than a week-by-week course [1].

General guidance for chronic constipation, from a 2020 Gastroenterology review, is to begin with dietary fiber supplementation and stimulant and/or osmotic laxatives, as appropriate [5]. That review is about chronic constipation in general, not about constipation caused by semaglutide.

What serious bowel problems does the label list?

Ileus and intestinal obstruction have been reported after Wegovy reached the market, but their frequency cannot be estimated [1].

The label says Wegovy should be discontinued if pancreatitis is suspected, and describes that pain as persistent or severe abdominal pain, sometimes radiating to the back, which may or may not come with nausea or vomiting [1].